Patents
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
06/2004
06/09/2004CN1152680C Pharmaceutical composition containing liphase inhibitors and chitosan
06/09/2004CN1152678C Pharmaceutical composition comprising lactobacillus plantarum and arginine
06/09/2004CN1152671C Multiple unit pharmaceutical preparation containing proton pump inhibitor
06/09/2004CA2452467A1 Novel methods for the treatment and prevention of pancreatitis and for induction of liver regeneration
06/08/2004US6747045 Such as 1-(3-(((3,4-dihydro-2h-1-benzopyran-2-yl)methyl) amino)-propyl)tetrahydro-2(1h)-pyrimidinone for treatment of irritable bowel syndrome and other gastrointestinal disorders
06/08/2004US6747035 Antiinflammatory agents; antiallergens
06/08/2004US6747034 CRF receptor antagonists and methods relating thereto
06/08/2004US6747032 Pyrimidin-4-one compounds
06/08/2004US6747031 N-heterocyclic derivatives as NOS inhibitors
06/08/2004US6747026 NK-1 receptor active amine oxide prodrugs
06/08/2004US6747022 Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
06/08/2004US6747016 Substituted purine derivatives as inhibitors of cell adhesion
06/08/2004US6747015 Low molecular weight polymannuronate
06/08/2004US6746671 Use of a cytokine-producing lactococcus strain to treat colitis
06/08/2004CA2307552C Substituted pyridine compounds as anti-inflammatory agents
06/03/2004WO2004046144A1 8-substituted imidazopyridines
06/03/2004WO2004046141A1 New tricyclic angiotensin ii agonists
06/03/2004WO2004046137A1 New tricyclic angiotensin ii agonists
06/03/2004WO2004046135A1 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
06/03/2004WO2004046134A2 Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
06/03/2004WO2004046128A1 New bicyclic angiotensin ii agonists
06/03/2004WO2004045718A2 Treatment of cognitive dysfunctions'
06/03/2004WO2004045631A1 The use of psoralea corylifolia for anti-infection caused by helicobacter pylori and for treatment of diseases caused by infection of helicobacter pylori
06/03/2004WO2004045615A1 Palonosetron for the treatment of chemotherapy-induced emesis
06/03/2004WO2004045612A1 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting
06/03/2004WO2004045606A1 Treatment of gastrointestinal disorders with duloxetine
06/03/2004WO2004045594A1 Agent for dissolving dental calculi and dental caries
06/03/2004WO2004024904A3 Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
06/03/2004WO2004019879A3 Motilide compounds
06/03/2004WO2004012726A3 Methods for treatment and prevention of gastrointestinal conditions
06/03/2004WO2003089619A3 Placental derived stem cells and uses thereof
06/03/2004WO2003089450A3 Fusion polypeptides and methods for inhibiting microbial adhesion
06/03/2004WO2003086371A3 Use of ep4 receptor ligands in the treatment of il-6 involved diseases
06/03/2004WO2003084937A3 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
06/03/2004WO2003075900A3 Utilization of ubiquinones for influencing the effect of histamine
06/03/2004WO2003063800A8 8-heteroaryl xanthine adenosine a2b receptor antagonists
06/03/2004WO2003051842A3 Compositions decreasing activity of hormone-sensitive lipase
06/03/2004WO2003048153A8 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
06/03/2004US20040107453 Multipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
06/03/2004US20040106800 cannabinoid (cb1); treating disorders involving cannabinoid neurotransmission
06/03/2004US20040106794 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
06/03/2004US20040106778 Interferon gamma-like protein
06/03/2004US20040106730 Polymer complexes of glucuronoglucanes
06/03/2004US20040106683 show selectivity to the MC1 and MC4 melanocortin receptors as agonists and/or antagonists
06/03/2004US20040106682 Novel benzylideneamino guanidines and their uses as ligands to the melnocortin receptors
06/03/2004US20040106675 class of compounds generally called the "statins" for use in stimulating bone formation and method to identify compounds useful in this regard by assessing their ability to inhibit enzymes in the pathway of isoprenoid synthesis
06/03/2004US20040106669 inhibitor against type-X sPLA2 (secretary PLA2) as an active ingredient
06/03/2004US20040106664 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
06/03/2004US20040106659 hydantoin, oxazoledione and thiazoledione (or dithiione) derivatives; e.g., 5-[1-(Biphenyl-4-yloxy)-ethyl]-5-methyl-imidazolidine-2,4-dione
06/03/2004US20040106656 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
06/03/2004US20040106655 pyrrolo-2yl-carbonyl-amino compounds; dipeptidyl peptidase inhibitor
06/03/2004US20040106654 Inhibitors of copper-containing amine oxidases
06/03/2004US20040106643 e.g., (1S,2R,3R,5R)-3-(3,4-Dichlorophenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid ethyl ester;
06/03/2004US20040106642 Polysubstituted imidazopyridines as gastric secretion inhibitors
06/03/2004US20040106641 e.g., N-(4-pyridylmethyl)-1-cyclopropylmethyl-7-azaindole-3-carboxylic acid amide
06/03/2004US20040106640 Aryl ether substituted imidazoquinolines
06/03/2004US20040106635 Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof
06/03/2004US20040106627 Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors
06/03/2004US20040106625 Therapeutic agents useful for treating pain
06/03/2004US20040106616 To treat one or more conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, cough, hiccup, and/or obesity
06/03/2004US20040106610 Antagonize pharmacological actions of the endogenous neuropeptide tachykinins known as neurokinins
06/03/2004US20040106568 Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation
06/03/2004US20040106565 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells
06/03/2004US20040106564 Use of slpi for treating chronic inflammatory intestinal diseases
06/03/2004US20040106561 comprises phytoestrogen isolated from red clover or soya, selected from genistein, daidzein, biochanin A, and/or formononetin; for treatment/prevention of cancer
06/03/2004US20040106559 for inhibiting proteases
06/03/2004US20040106539 Agents for the treatment of viral infections
06/03/2004US20040106196 Systems and methods for treating patients with processed lipoaspirate cells
06/03/2004US20040106155 Method for kidney disease treatment by drug intervention
06/03/2004US20040105862 Human TIMP-1 antibodies
06/03/2004US20040105838 Orlistat compositions
06/03/2004DE10133305B4 Ubichinon Konzentrat Ubiquinone concentrate
06/03/2004CA2506673A1 Treatment of gastrointestinal disorders with duloxetine
06/03/2004CA2506027A1 8-substituted imidazopyridines
06/02/2004EP1424393A2 Mammalian cytokine-like polypeptide-10
06/02/2004EP1424337A1 4-hydroxy derivatives of 5,6,9,10-tetrahydro-10-((2-methyl-1h-imidazol-1-yl)methyl)-4h-pyrido-(3,2,1-jk)-carbazol-11(8h)-one
06/02/2004EP1424336A1 1,3-benzothiazinone derivatives and use thereof
06/02/2004EP1424335A1 Indole derivatives
06/02/2004EP1424326A1 Fused-polycyclic compounds
06/02/2004EP1424325A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
06/02/2004EP1424073A1 Anti diarrhoea compositions
06/02/2004EP1424067A1 Injectable foam and novel pharmaceutical applications thereof
06/02/2004EP1423697A2 Secreted proteins
06/02/2004EP1423525A1 Recombinant mva capable of expressing structural hcv antigens
06/02/2004EP1423511A2 Nucleic-acid associated proteins
06/02/2004EP1423424A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology
06/02/2004EP1423422A2 A caspase- 8 binding protein, its preparation and use
06/02/2004EP1423415A2 Intracellular signaling molecules
06/02/2004EP1423413A1 Peptidic compounds selectively binding to p-selectin
06/02/2004EP1423409A2 Gastrokines and derived peptides including inhibitors
06/02/2004EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
06/02/2004EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7
06/02/2004EP1423386A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
06/02/2004EP1423382A2 Pyrazole-derived kinase inhibitors and uses thereof
06/02/2004EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof
06/02/2004EP1423366A1 Cyclopenta b ! indole derivatives as spla2 inhibitors
06/02/2004EP1423356A2 Novel aminobenzoephenones
06/02/2004EP1423142A1 Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins
06/02/2004EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/02/2004EP1423126A2 Treatment of hyperproliferative conditions of body surfaces